Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Serological Analysis of Tuberculosis in Goats by Use of the Enferplex Caprine TB Multiplex Test.

O'Brien A, Whelan C, Clarke JB, Hayton A, Watt NJ, Harkiss GD.

Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00518-16. doi: 10.1128/CVI.00518-16. Print 2017 Feb.

2.

Effect of retinal and/or extra-retinal information on age in memory-guided saccades.

Burke MR, Clarke JB, Hedley J.

Exp Brain Res. 2010 Aug;205(1):87-94. doi: 10.1007/s00221-010-2335-y. Epub 2010 Jun 26.

PMID:
20582538
3.

Mechanisms of adverse drug reactions to biologics.

Clarke JB.

Handb Exp Pharmacol. 2010;(196):453-74. doi: 10.1007/978-3-642-00663-0_16. Review.

PMID:
20020272
4.

Characterisation of five factor XI mutations.

Mitchell MJ, Dai L, Clarke JB, Bolton-Maggs PH, Savidge GF, Alhaq A.

Thromb Haemost. 2007 Jun;97(6):884-9.

PMID:
17549289
5.

Identification of molecular markers linked to the mildew resistance gene Pl-d in apple.

James CM, Clarke JB, Evans KM.

Theor Appl Genet. 2004 Dec;110(1):175-81. Epub 2004 Nov 13.

PMID:
15551035
6.

Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells.

Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM.

Biochem Biophys Res Commun. 2002 Jun 28;294(5):995-1000.

PMID:
12074575
7.

A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells.

Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM.

Biochem Biophys Res Commun. 2002 Jun 28;294(5):988-94.

PMID:
12074574
8.
11.

Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.

Imai Y, Moralez A, Andag U, Clarke JB, Busby WH Jr, Clemmons DR.

J Biol Chem. 2000 Jun 16;275(24):18188-94.

12.

Complex mediation of uterine endometrial epithelial cell growth by insulin-like growth factor-II (IGF-II) and IGF-binding protein-2.

Badinga L, Song S, Simmen RC, Clarke JB, Clemmons DR, Simmen FA.

J Mol Endocrinol. 1999 Dec;23(3):277-85.

PMID:
10601973
13.

Hermeneutic analysis: a qualitative decision trail.

Clarke JB.

Int J Nurs Stud. 1999 Oct;36(5):363-9.

PMID:
10519680
15.

Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions.

Clemmons DR, Busby W, Clarke JB, Parker A, Duan C, Nam TJ.

Endocr J. 1998 Apr;45 Suppl:S1-8. Review. No abstract available.

16.

A protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions.

Rees C, Clemmons DR, Horvitz GD, Clarke JB, Busby WH.

Endocrinology. 1998 Oct;139(10):4182-8.

PMID:
9751498
17.

Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin.

Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR.

Endocrinology. 1998 Apr;139(4):1708-14.

PMID:
9528953
18.

Academic validation of prior and experiential learning: evaluation of the process.

Clarke JB, Warr J.

J Adv Nurs. 1997 Dec;26(6):1235-42.

PMID:
9429976
19.

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Imai Y, Busby WH Jr, Smith CE, Clarke JB, Garmong AJ, Horwitz GD, Rees C, Clemmons DR.

J Clin Invest. 1997 Nov 15;100(10):2596-605.

20.

Detection of human viruses using primary cells immortalised by oncogene transfection, in comparison with primary cells and established cell lines.

Clarke JB, Philpotts R, Chakraverty P, Kreuzberg-Duffy U, MacDonald C, Moulsdale H, Golding J, Peters J, Griffiths JB.

J Med Virol. 1996 Oct;50(2):176-80. Erratum in: J Med Virol 1997 Jun;52(2):234.

PMID:
8915884
21.

Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5.

Parker A, Clarke JB, Busby WH Jr, Clemmons DR.

J Biol Chem. 1996 Jun 7;271(23):13523-9.

22.

Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.

Clarke JB, Thomas C, Chen M, Hastings KL, Gandolfi AJ.

Int Arch Allergy Immunol. 1995 Sep;108(1):24-32.

PMID:
7647582
23.
24.

Role of insulin-like growth factor binding proteins in the control of IGF actions.

Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, Ankrapp DK.

Prog Growth Factor Res. 1995;6(2-4):357-66. Review.

PMID:
8817679
25.

CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors.

Wright KL, Vilen BJ, Itoh-Lindstrom Y, Moore TL, Li G, Criscitiello M, Cogswell P, Clarke JB, Ting JP.

EMBO J. 1994 Sep 1;13(17):4042-53.

27.

Immunogenicity studies of a synthetic antigen of alpha methyl dopa.

Hubbard AK, Lohr CL, Hastings K, Clarke JB, Gandolfi AJ.

Immunopharmacol Immunotoxicol. 1993 Nov;15(5):621-37.

PMID:
8301021
28.

Ethical issues in health education.

Clarke JB.

Br J Nurs. 1993 May 27-Jun 9;2(10):533-8.

PMID:
8324353
29.

A view of the phenomenon of caring in nursing practice.

Clarke JB, Wheeler SJ.

J Adv Nurs. 1992 Nov;17(11):1283-90.

PMID:
1430633
30.

Conjugation of dinitrofluorobenzene to plasma proteins in vivo in the rat.

Kitteringham NR, Kenna JG, McLean C, Clarke JB, Park BK.

Drug Metab Dispos. 1992 Sep-Oct;20(5):625-31.

PMID:
1358565
31.

The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA.

Zeleznik-Le NJ, Itoh-Lindstrom Y, Clarke JB, Moore TL, Ting JP.

J Biol Chem. 1992 Apr 15;267(11):7677-82.

32.

The mechanism of bioactivation and antigen formation of amodiaquine in the rat.

Harrison AC, Kitteringham NR, Clarke JB, Park BK.

Biochem Pharmacol. 1992 Apr 1;43(7):1421-30.

PMID:
1567466
33.

Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine.

Clarke JB, Neftel K, Kitteringham NR, Park BK.

Int Arch Allergy Appl Immunol. 1991;95(4):369-75.

PMID:
1959977
34.

The effect of bioreactor configuration on production of HIV and cell-virus interaction.

Clarke JB, Griffiths JB.

Cytotechnology. 1990 Sep;4(2):145-53.

PMID:
1367042
35.

Alternative ligands as probes for the carotenoid-binding site of lobster carapace crustacyanin.

Clarke JB, Eliopoulos EE, Findlay JB, Zagalsky PF.

Biochem J. 1990 Feb 1;265(3):919-21.

36.

Influence of glutathione conjugation on the immunogenicity of dinitrophenyl derivatives in the rat.

Tingle MD, Clarke JB, Kitteringham NR, Park BK.

Int Arch Allergy Appl Immunol. 1990;91(2):160-5.

PMID:
2341195
37.

Immunogenicity of amodiaquine in the rat.

Clarke JB, Maggs JL, Kitteringham NR, Park BK.

Int Arch Allergy Appl Immunol. 1990;91(4):335-42.

PMID:
2210868
38.

Chipping hammer vibration.

Clarke JB, Dalby W, Gunn JF.

Scand J Work Environ Health. 1986 Aug;12(4 Spec No):351-4.

39.

Mechanism of action of rabbit liver phosphoglucomutase.

Jamil H, Clarke JB.

Biochem J. 1985 Sep 15;230(3):791-5.

40.

Transformation and foot and mouth disease virus (FMDV) productivity of some BHK cell lines.

Clarke JB.

Acta Virol. 1983 Nov;27(6):534. No abstract available.

PMID:
6140842
41.
42.

Veiled (dendritic) cells in synovial fluid.

de Vere Tyndall A, Knight SC, Edwards AJ, Clarke JB.

Lancet. 1983 Feb 26;1(8322):472-3. No abstract available.

PMID:
6131189
43.

Mechanism of action of rabbit liver phosphoglucomutase.

Jamil H, Clarke JB.

Biochem Soc Trans. 1981 Feb;9(1):63-4. No abstract available.

PMID:
6452301
45.

Accuracy and Speed in Counting Agar Plates 1.

Fruin JT, Idll TM, Clarke JB, Fowler JL, Guthertz LS.

J Food Prot. 1977 Sep;40(9):596-599. doi: 10.4315/0362-028X-40.9.596.

PMID:
30731586
47.

The equilibrium constant of the phosphoglyceromutase reaction.

Clarke JB, Birch M, Britton HG.

Biochem J. 1974 Jun;139(3):491-7.

48.

The mechanism of phosphoglucomutase from Micrococcus lysodeikticus.

Clarke JB, Britton HG.

Biochem J. 1974 Mar;137(3):453-61.

49.
50.

The reactive serine residue in phosphoglucomutase of Micrococcus lysodeikiticus.

Milstein CP, Clarke JB, Britton HG.

Biochem J. 1973 Nov;135(3):551-3.

Supplemental Content

Loading ...
Support Center